Mapping of Lymph Node Metastasis and Survival For pN+ Superficial Esophageal Squamous Cell Carcinoma

With the deeper tumor invasion, the higher LNM rate beside the bilateral recurrent laryngeal nerves(RLN) was.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

National Cancer Center/Cancer Hospital

Age range

44 year–73 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Our predefined search strategy identified pT1N+ ESCC cases without preoperative treatment, between February 2012 and April 2022.

Exclusion criteria

The patients were excluded because they were (1)less than 10 lymph nodes removed; (2) lacked specific sites of LNM; or (3) incomplete follow-up information.

Treatment and study plan

Esophagectomy

Procedure

McKeown, Ivor-Lewis, and Sweet procedure

Primary outcomes

LNM rates of the 207 thoracic T1N+ ESCC patients.

Time frame: 2012.2-2022.4

Sponsors and collaborators

Lead sponsor

National Cancer Center, China

Other

Registry information

Official study title

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Important dates

Study start: 2012
Primary completion: 2022
Study completion: 2022
First posted: Sep 2, 2022
Registry last updated: Sep 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.